CN102349919B - Application of gingkolic acid in preparation of external preparation for treating osmidrosis - Google Patents
Application of gingkolic acid in preparation of external preparation for treating osmidrosis Download PDFInfo
- Publication number
- CN102349919B CN102349919B CN 201110236658 CN201110236658A CN102349919B CN 102349919 B CN102349919 B CN 102349919B CN 201110236658 CN201110236658 CN 201110236658 CN 201110236658 A CN201110236658 A CN 201110236658A CN 102349919 B CN102349919 B CN 102349919B
- Authority
- CN
- China
- Prior art keywords
- gingkolic acid
- acid
- external preparation
- gingkolic
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 title claims abstract description 139
- 238000002360 preparation method Methods 0.000 title claims abstract description 66
- 241000218628 Ginkgo Species 0.000 claims abstract description 37
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 37
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 37
- 210000004243 sweat Anatomy 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 12
- 239000002537 cosmetic Substances 0.000 claims abstract description 5
- 239000000645 desinfectant Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 27
- 210000000582 semen Anatomy 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 4
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 3
- 230000037371 chromhidrosis Effects 0.000 claims description 3
- 208000015318 chromhidrosis Diseases 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000037315 hyperhidrosis Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 7
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 235000021588 free fatty acids Nutrition 0.000 abstract description 6
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 abstract description 5
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 abstract description 3
- 210000004907 gland Anatomy 0.000 abstract description 2
- 210000002640 perineum Anatomy 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229910017464 nitrogen compound Inorganic materials 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 20
- 210000000106 sweat gland Anatomy 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000000605 extraction Methods 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 208000035985 Body Odor Diseases 0.000 description 15
- 206010055000 Bromhidrosis Diseases 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 210000000040 apocrine gland Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 229940098465 tincture Drugs 0.000 description 11
- 210000005239 tubule Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- -1 terpene lactone chemical compound Chemical class 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 238000005121 nitriding Methods 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- CPGCVOVWHCWVTP-LJAQVGFWSA-N (S)-nonacosan-10-ol Chemical compound CCCCCCCCCCCCCCCCCCC[C@@H](O)CCCCCCCCC CPGCVOVWHCWVTP-LJAQVGFWSA-N 0.000 description 1
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- DNTSXRMSSGNLFL-UHFFFAOYSA-N Hydroginkgolinic acid Natural products CCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O DNTSXRMSSGNLFL-UHFFFAOYSA-N 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022088 Injection site paraesthesia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- CVTZKFWZDBJAHE-UHFFFAOYSA-N [N].N Chemical class [N].N CVTZKFWZDBJAHE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000014398 anacardic acid Nutrition 0.000 description 1
- KAOMOVYHGLSFHQ-UTOQUPLUSA-N anacardic acid Chemical compound CCC\C=C/C\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O KAOMOVYHGLSFHQ-UTOQUPLUSA-N 0.000 description 1
- ADFWQBGTDJIESE-UHFFFAOYSA-N anacardic acid 15:0 Natural products CCCCCCCCCCCCCCCC1=CC=CC(O)=C1C(O)=O ADFWQBGTDJIESE-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- CPGCVOVWHCWVTP-UHFFFAOYSA-N celidoniol Natural products CCCCCCCCCCCCCCCCCCCC(O)CCCCCCCCC CPGCVOVWHCWVTP-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000804 eccrine gland Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical group 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- YFDLHELOZYVNJE-UHFFFAOYSA-L mercury diiodide Chemical compound I[Hg]I YFDLHELOZYVNJE-UHFFFAOYSA-L 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to application of gingkolic acid in preparation of an external preparation for treating osmidrosis. The gingkolic acid comprises ginkgoic acid, ginkgol, ginkgo diphenol and the like, and can be extracted from leaf, fruit, external exotesta, rhizome and other parts of ginkgo through a chemical separation method. The osmidrosis includes the osmidrosis of axillary part, foot part, perineum and other parts. The drug, cosmetic or disinfectant external preparation containing gingkolic acid for treating osmidrosis contains 0.001-80wt% of gingkolic acid and a pharmaceutically common external preparation matrix or acceptable carrier; and the preparation is any one pharmaceutically external dosage form. Pharmacological experiment researches show that the external preparation has the effects of inhibiting the growth and propagation of bacteria on skin surface and permeating into skin to destroy large sudoriferous gland, and inhibiting the generation of free fatty acid, ammonia nitrogen compound and other smelling substances in sweat. Clinical trial shows that the external preparation has significant treatment effect on the osmidrosis, has effective rate up to 100%, is safe to use and has no side effect.
Description
Technical field
The invention belongs to biological medicine and therapeutic make-up technique field, be specifically related to the purposes of gingkolic acid in the external preparation of preparation treatment fetid sweat.
Background technology
Fetid sweat can be divided into general fetid sweat and local fetid sweat, and the latter is comparatively common with bromhidrosis and foot odor.Bromhidrosis is a kind of common heritability skin metabolism disease, is commonly called as bromhidrosis, mainly shows as the armpit abnormal flavour, and some cases merges maschalephidrosis, and the order of severity varies with each individual.The sweat gland of human body comprises eccrine gland and apocrine gland, apocrine gland claims apocrine sweat gland, foul smell gland again, is distributed in positions such as axillary fossa, perineum, foot, groin and mammary areola, is positioned at corium and subcutaneous tissue intersection and subcutaneous tissue, be opened on hair follicle, Excreta is discharged skin surface along hair shaft.The apocrine gland liquid of just having discharged skin surface is creamy white, tasteless, contain protein, lipid, fatty acid, cholesterol, gluconic acid, compositions such as amine, the main cause of fetid sweat is the organic substance of excessive secretion in the perspiration drained of apocrine gland, be subjected to skin surface antibacterial (staphylococcus epidermidis, staphylococcus aureus, staphylococcus saprophyticus and gram negative bacilli diphtheroid, corynebacterium etc.) decomposition, produce six carbon to ten carbon short chain unsaturated fatty acids and micromolecule ammonia nitriding compound, as caproic acid, sad, different valerian element, butanoic acid and mercaptan, amine, metabolism products such as indole and produce unpleasant stink.Therefore destroy the key that apocrine gland is considered to the bromhidrosis radical cure.Because the secretory function of apocrine gland is subjected to the influence of androgen, the pubarche activity is degenerated to old, therefore bromhidrosis originates from adolescence, the between twenty and fifty phase is comparatively serious, makes the patient be subjected to physiology and psychological dual-pressure in social life, so thoroughly effective treatment is very important.
The method for the treatment of at present bromhidrosis disease clinically is a lot, roughly can be summarized as conservative treatment and operation method, and conservative treatment mainly comprises: external used medicine, injection, physiotherapy (microwave, freezing, electricity coagulates, laser) etc.The local topical medicine comprises topical application antibiotics, fragrant and deodorizing agent, antiperspirant, chemical hormone etc., its objective is to reduce skin of axillary fossa perspire, control bacterial invasion or hide niff, thus relief of symptoms; But at present there is the curative effect weak point of holding time in local application, easily recurrence, after part patient's drug withdrawal bounce-back more serious, can not reach the effect of real radical cure; Also multiple untoward reaction can occur, as anaphylaxiss such as agents area are rubescent, itch, and in various degree symptoms such as pachylosis, pigmentation, desquamation occur; The chemistry hormone causes sclerosis of the skin easily, and more refractory is treated later on, should avoid using this class medicine as far as possible.The subcutaneous injection botulinum toxin can suppress sweat gland secretion, but effect is subjected to the influence of individual variation, and it is not lasting to act on, and needs injection repeatedly; And be prone to injection site paraesthesia and stasis of blood purple, meeting forms antibody and influences therapeutic effect in the multiple injection body.The laser therapy method can cause the hot injury to skin and surrounding tissue in therapeutic process, and exists treatment not thorough, and there is the shortcoming of higher recurrent rate in postoperative.At present, remove the method that part armpit skin histology is the radical cure bromhidrosis disease used always by operation method, but the method can be brought wound and misery to the patient, the possibility that comprise pain, hemorrhage, infection of incisional wound, the cicatricial contracture influence is attractive in appearance and a series of complication such as function take place, even influence upper extremity function, still have certain relapse rate after the operation, so excision is not accepted by most of bromhidrosis patients.
For fear of the generation of this type of bad phenomenon, market demand develop a kind of derive from natural, effect significantly, the external preparation of the treatment fetid sweat of no obvious adverse reaction, to alleviate the patient suffering.Fetid sweat patient is numerous, and the external preparation product of developing this type for the treatment of fetid sweat has good potential applicability in clinical practice, is very useful and necessary to the patient.
Semen Ginkgo is the medicinal plants of China's preciousness, and the leaf of Semen Ginkgo, fruit and episperm etc. all have medicinal exploitation and be worth.According to the Compendium of Material Medica record, Semen Ginkgo property is sweet, bitter, flat, puckery; Have that relieving asthma and cough, leukorrhagia stopping are turbid, the merit of pain relieving; Cure mainly cough of cold type phlegm dyspnea, asthma, frequent micturition, leucorrhea with red and white discharge, rhagadia manus et pedis etc.It is found that in recent decades particularly and contain plurality of active ingredients in the Folium Ginkgo that main effective ingredient is flavonoid and terpene lactone chemical compound, has the function of control cardiovascular and cerebrovascular disease.China has the gingko episperm soak is used as pesticide morning among the people, and insects such as aphid, rice borer are had killing action.
Gingkolic acid is colourless or flaxen oily or powdered substance, is to be present in that a class has the component of important physiologically active in Folium Ginkgo, fruit and the episperm.Gingkolic acid involved in the present invention is alkyl or alkenyl phenol acid, according to whether being connected with carboxyl on the phenyl ring in the molecule, it is divided into ginkgoic acid and ginkgol two big classes.Ginkgoic acid is the salicylic acid molecule has saturated or unsaturated chain alkyl in phenyl ring C6 position series compound, can be divided into 5 kinds by chemical constitution, and side chain R is C
13H
27, C
15H
29, C
15H
31, C
17H
31And C
17H
33, corresponding molecular weight is respectively 320,346,348,372,374.Gingkolic acid comprises ginkgolic acid, hydroginkgoic acid, Semen Ginkgo eo-acid, the inferior acid of Semen Ginkgo, hydroginkgolinic acid, anacardic acid, ginkgol, Semen Ginkgo diphenol, Ginnol etc.Gingkolic acid (ginkgoic acid, ginkgol, Semen Ginkgo diphenol) structure See Figure.
The structure of gingkolic acid
Along with going deep into gradually that the separating Ginkgo phenolic acids material is studied, find that gingkolic acid has multiple biological activity.There are some researches show that gingkolic acid has good inhibition effect to external various bacteria, can suppress the growth of the former bacterium of part agricultural disease; Gingkolic acid has good inhibition effect to the growth of tumor cell line.About extraction, analysis and the antibacterial activity in vitro of gingkolic acid, anti-agriculture pathogen and protozoon, the existing bibliographical information of anti-tumor activity.Have not yet to see the report of the purposes of gingkolic acid in the external preparation of preparation treatment fetid sweat.Therefore, relevant gingkolic acid external preparation is prevented and treated the research and development of fetid sweat newtype drug, cosmetics, disinfectant, and to the abundant development and use of gingko resource, will produce huge social and economic benefit.
Summary of the invention
The new purposes that the purpose of this invention is to provide gingkolic acid, the i.e. purposes of gingkolic acid in the external preparation of preparation treatment fetid sweat.It has good deodorization effect, characteristics evident in efficacy, as not recur, use safety.
The object of the present invention is achieved like this:
The purposes of gingkolic acid in treatment fetid sweat, hyperhidrosis, chromhidrosis is provided.
The purposes of gingkolic acid in the external preparation of preparation treatment fetid sweat, hyperhidrosis, chromhidrosis is provided.
Described fetid sweat is armpit, foot, perineal position fetid sweat etc.
Described gingkolic acid comprises ginkgoic acid, ginkgol, Semen Ginkgo diphenol etc., can be by the Chemical Decomposition method, from the leaf of Semen Ginkgo, really, obtain the extract at position such as episperm, rhizome; Or to Folium Ginkgo, really, episperm, rhizome extract elaboration products and reclaim again in the remaining waste material in extracting the course of processing; Or from containing the each several part extract of this compounds, other plant obtains; Or the method by chemosynthesis obtains.Materials such as claimed this compounds of the present invention and pharmaceutically acceptable salt thereof, ester, solvate, crystal habit.
Medicine, cosmetics or the disinfectant external preparation of the treatment fetid sweat that contains gingkolic acid also are provided, contain gingkolic acid 0.001-80%, by weight percentage, and external preparation substrate or the external preparation acceptable carrier pharmaceutically used always.
Further, contain gingkolic acid 0.001-30%, by weight percentage.
Further, contain gingkolic acid 0.5-20%, by weight percentage.
By above-mentioned weight ratio scope get the principal agent gingkolic acid, external preparation substrate or acceptable carrier pharmaceutically commonly used prepares the gingkolic acid external preparation; And comprise medicine, cosmetics or the disinfectant external preparation that gingkolic acid and any combinations of substances are used for the treatment of fetid sweat.Described preparation is said exterior-applied formulation on any pharmaceutics, can be liquid preparation, cream cream, gel, powder, membrane, lotion, aerosol spray, transdermal absorption formulation, subcutaneous injection agent etc.
The invention has the beneficial effects as follows, the pharmacology pharmacodynamic experimental study shows, gingkolic acid external preparation of the present invention has and suppresses the breeding of skin surface bacterial growth, suppresses sweat gland secretion, infiltrates skin and destroy apocrine gland, inhibition and reduce the effect that free fatty acid and ammonia nitriding compound odor causing substance produce in the perspiration, but can not influence the sweat gland function of normal skin.Fetid sweat had significant therapeutical effect.The local irritation experimentation shows safety of the present invention, untoward reaction such as no skin irritation, allergy.Clinic trial result shows that the present invention has significant therapeutical effect to fetid sweat, and effective percentage reaches 100%, uses safety to have no side effect.
The specific embodiment
Below in conjunction with embodiment, the present invention is done to describe further.
Embodiment 1:
The gingkolic acid extraction process is as follows in the ginkgo nut episperm: the ginkgo nut episperm is stripped down, dry, with pulverizer it is pulverized.Accurately take by weighing a certain amount of gingko episperm through pulverizing, adding solid-liquid ratio is 80% ethanol of 1: 6 (W/V), under 60 ℃ of bath temperatures, stirring and leaching 2 times, (is annotated: behind the liquid feeding at each 4 hours extraction times, the beaker mouth seals with preservative film, to prevent the volatilization of ethanol).Lixiviate is used the nutsch filter sucking filtration after finishing, and collects filtrate.With rotary evaporation in vacuo instrument concentrated filtrate, condition is 55 ℃ of temperature, pressure 0.008-0.009MPa, concentrating under reduced pressure.In 60 ℃ of vacuum dryings, get gingkolic acid extractum, character is: light brown extractum, little smelly, be dissolved in alcohol, water insoluble; Weigh, and measure gingkolic acid content (mg/g).
Gingkolic acid assay: adopt the HPLC method to measure.The standard solution of gingkolic acid is between 100-1200 μ g/ml, and respective peaks area and gingkolic acid mass concentration have significant linear relationship, have worked out standard curve., filter the dissolving of gingkolic acid extractum with dehydrated alcohol (chromatographically pure).At column temperature: room temperature; Mobile phase: methanol-water (9: 1, v/v); Flow velocity 1ml/min; Sample size: 20 μ l; Detect wavelength 310nm; Analysis time: measure gingkolic acid content in the extractum under the 25min condition.Carry out qualitatively according to the retention time of standard specimen, calculate the content of gingkolic acid with external standard method.Gingkolic acid content is 637.17mg/g in the extractum.
Gingkolic acid extraction process and content assaying method are public method.
The preparation of gel: carbopol 10g is sprinkled upon 500ml distilled water surface, and swelling is spent the night.Take by weighing glycerol 60g, propylene glycol 120ml is added to respectively in the good carbopol of swelling, grinds evenly rapidly, obtains transparent gel-type vehicle.Get above-mentioned gingkolic acid extractum 40g, be dissolved in the 100ml95% alcoholic solution, slowly be added in the gel-type vehicle, stir.Slowly add triethanolamine 15ml again, mend distilled water to capacity 1000g, namely get faint yellow gingkolic acid gel 1000g, gingkolic acid content is 2.55% (W/W).Be sub-packed in 50 tubules every 20g.
Gel preparation technology is public method.
Embodiment 2:
The gingkolic acid extraction process is as follows in the Semen Ginkgo fruit Semen Ginkgo: with the Semen Ginkgo peeling, put into tissue mashing machine and pulverize.Accurately take by weighing a certain amount of Semen Ginkgo through pulverizing, adding solid-liquid ratio is 80% ethanol of 1: 10 (W/V), under 60 ℃ of bath temperatures, and stirring and leaching 2 times, each 4 hours extraction times, (annotate: behind the liquid feeding, the beaker mouth seals with preservative film, to prevent the volatilization of ethanol).After lixiviate finished, centrifugal (5000 rev/mins, 15 minutes) got supernatant.With rotary evaporation in vacuo instrument concentrated supernatant, condition is 55 ℃ of temperature, pressure 0.008-0.009MPa, and concentrating under reduced pressure, and in 60 ℃ of vacuum dryings, get gingkolic acid extractum, and character is: light brown extractum, and little smelly, be dissolved in alcohol, water insoluble.Weigh, and measure gingkolic acid content (mg/g).
Gingkolic acid assay: with embodiment 1.Gingkolic acid content is 475.38mg/g in the extractum.
The preparation of ointment: get above-mentioned gingkolic acid extractum 40g, be dissolved in the 100ml95% alcoholic solution, to wherein adding triethanolamine 50ml, heat to 70 ℃ again.Paraffin 300g, stearic acid 300g, propylene glycol 100ml are added stirring respectively melt, mend distilled water to capacity 1000g, stir to paste, namely get faint yellow gingkolic acid ointment 1000g, gingkolic acid content is 1.9% (W/W).Be sub-packed in 50 tubules every 20g.
Ointment preparation technology is public method.
Embodiment 3:
The gingkolic acid extraction process is as follows in the Folium Ginkgo: Folium Ginkgo is shredded, put into pulverizer with its pulverizing.Accurately take by weighing a certain amount of Folium Ginkgo through pulverizing, adding solid-liquid ratio is 80% ethanol of 1: 6 (W/V), under 60 ℃ of bath temperatures, stirring and leaching 2 times, (is annotated: behind the liquid feeding at each 4 hours extraction times, the beaker mouth seals with preservative film, to prevent the volatilization of ethanol).After lixiviate finished, centrifugal (5000 rev/mins, 15 minutes) got supernatant.With rotary evaporation in vacuo instrument concentrated supernatant, condition is 55 ℃ of temperature, pressure 0.008-0.009MPa, and concentrating under reduced pressure, and in 60 ℃ of vacuum dryings, get gingkolic acid extractum, and character is: light brown extractum, and little smelly, be dissolved in alcohol, water insoluble.Weigh, and measure gingkolic acid content (mg/g).
Gingkolic acid assay: with embodiment 1.Gingkolic acid content is 526.73mg/g in the extractum.
The preparation of tincture: get above-mentioned gingkolic acid extractum 80g, be dissolved in the 600ml95% alcoholic solution, again to wherein adding triethanolamine 50ml respectively, propylene glycol 200ml stirs, mend 95% alcoholic solution to capacity 1000ml, namely get faint yellow gingkolic acid tincture 1000ml, gingkolic acid content is 4.2% (W/V).Be sub-packed in 50 tubules every 20ml.
Tincture preparation technology is public method.
Embodiment 4:
Gingkolic acid extraction process and content assaying method get gingkolic acid extractum with embodiment 1 in the ginkgo nut episperm, and gingkolic acid content is 626.19mg/g.Get gingkolic acid extractum 80g, prepare gingkolic acid gel 1000g by embodiment 1 gel preparation technology, gingkolic acid content is 5% (W/W).Be sub-packed in 50 tubules every 20g.
Embodiment 5:
The gingkolic acid extraction process is with embodiment 2 in the Semen Ginkgo fruit Semen Ginkgo, and content assaying method gets gingkolic acid extractum with embodiment 1, and gingkolic acid content is 527.17mg/g.Get gingkolic acid extractum 10g, prepare gingkolic acid ointment 1000g by embodiment 2 ointment preparation technologies, gingkolic acid content is 0.53% (W/W).Be sub-packed in 50 tubules every 20g.
Embodiment 6:
The gingkolic acid extraction process is with embodiment 3 in the Folium Ginkgo, and content assaying method gets gingkolic acid extractum with embodiment 1, and gingkolic acid content is 529.11mg/g.Get gingkolic acid extractum 200g, prepare gingkolic acid tincture 1000ml by embodiment 3 tincture preparation technologies, gingkolic acid content is 10.6% (W/V).Be sub-packed in 50 tubules every 20ml.
Embodiment 7:
Gingkolic acid extraction process and content assaying method get gingkolic acid extractum with embodiment 1 in the ginkgo nut episperm, and gingkolic acid content is 628.23mg/g.Get gingkolic acid extractum 300g, prepare gingkolic acid tincture 1000ml by embodiment 3 tincture preparation technologies, gingkolic acid content is 18.85% (W/V).Be sub-packed in 50 tubules every 20ml.
Embodiment 8:
The gingkolic acid extraction process is with embodiment 3 in the Folium Ginkgo, and content assaying method gets gingkolic acid extractum with embodiment 1, and gingkolic acid content is 551.78mg/g.Get gingkolic acid extractum 200g, prepare gingkolic acid gel 1000g by embodiment 1 gel preparation technology, gingkolic acid content is 11% (W/W).Be sub-packed in 50 tubules every 20g.
Embodiment 9:
Gingkolic acid extraction process and content assaying method get gingkolic acid extractum with embodiment 1 in the ginkgo nut episperm, and gingkolic acid content is 663.62mg/g.Get gingkolic acid extractum 500g, prepare gingkolic acid tincture 1000ml by embodiment 3 tincture preparation technologies, gingkolic acid content is 33.2% (W/V).Be sub-packed in 50 tubules every 20ml.
Embodiment 10:
The gingkolic acid extraction process is with embodiment 2 in the Semen Ginkgo fruit Semen Ginkgo, and content assaying method gets gingkolic acid extractum with embodiment 1, and gingkolic acid content is 435.57mg/g.Get gingkolic acid extractum 1g, prepare gingkolic acid ointment 1000g by embodiment 2 ointment preparation technologies, gingkolic acid content is 0.044% (W/W).Be sub-packed in 50 tubules every 20g.
In order to the gingkolic acid external preparation that the top method is made, the pharmacology pharmacodynamic of being correlated with test, the experiment of local irritation safety evaluatio and clinic trial test.Be experimental data of the present invention below:
Influence to rat paw portion sweat gland secretion: the sweat gland excitation time, except sweat secretion increased, the visible sweat gland epithelial cell cavity of microscopically number increased.20 of rats are divided 2 groups at random, model control group and gingkolic acid gel group of the present invention, 10 every group.Each rat foot of gingkolic acid gel group of the present invention is coated with gingkolic acid gel of the present invention respectively outward, and each rat foot of model control group is outer respectively to be coated with physiological saline solution, every day 1 time, continuous 7 days.Last is smeared and was put to death rat in back 24 hours, neat ankle is blocked two hind legs, take off two sole of the foot portion meat lift skins and subcutaneous tissue 2-3 piece, the variation of respectively organizing in the rat paw sweat gland epithelial cell is observed in fixing, dehydration according to a conventional method, embedding, section, HE dyeing under the optical microscope.Cavity generation percentage rate=cavity sweat gland number/observation sweat gland is counted X100%.Experimental result sees Table 1.The result shows that gingkolic acid gel of the present invention can obviously reduce rat paw portion sweat gland cavity incidence rate, and sweat gland is had the obvious suppression effect.
The influence of table 1. pair rat paw portion sweat gland secretion
X ± s.n=10. compares with model group, * P＜0.05, * * P＜0.01.
The separation of application on human skin apocrine gland cell and external former be commissioned to train foster: get 5 of about 0.5cmX0.5cm sizes of apocrine gland tissue behind the bromhidrosis patient surgical operation, place the HBSS liquid that contains penicillin (100U/ml) and streptomycin (100 μ g/ml) repeatedly after the rinsing, in the 60mm culture dish, be cut into fritter about 1mm3 with eye scissors, add DMEM/F12 (1: 1) the liquid 3ml contain II Collagen Type VI enzyme (2mg/ml), hyclone (5%), penicillin (100U/ml) and streptomycin (100 μ g/ml), put in 37 ℃, 5%CO2 incubator and spend the night.Shift sweat gland next day and fill in the 60mm culture dish of 600 μ l sweat gland culture fluid in another, put under 37 ℃, 5%CO2 condition and cultivate; The sweat gland culture fluid as basic culture solution, is added hyclone (5%), recombinant human epidermal growth factor (10ng/ml), the former ammonia of triiodo thyroid (2ng/ml), half succinyl hydrocortisone (0.4 μ g/ml), insulin-transferrins-sodium selenite (1ml/100ml), penicillin (100U/ml), streptomycin (100 μ g/ml) with DMEM/F12 (1: 1).After treating that sweat gland is adherent, add about 2ml sweat gland culture fluid and continue to cultivate, later every 2-3d changes liquid 1 time, puts under 37 ℃, 5%CO2 condition and cultivates.
Going down to posterity of application on human skin apocrine gland cell cultivated and vitality test: after cultured skin sweat gland cells about 80% merges, and the feasible cultivation of going down to posterity.Centrifugal collecting cell, adopt tetramethyl azo azoles salt (MTT) colorimetric determination cell proliferation vigor, cell inoculation in 96 orifice plates (every porocyte number is 2 * 103), is established 6 drug dose groups, add gingkolic acid tincture 0 of the present invention respectively, 10,20,40,60,80,100 μ l, each dosage group is established 12 multiple holes; Cultivate after 3 days, the sucking-off culture fluid, add MTT solution 100 μ l in every hole in 37 ℃ of reactions 4 hours, discard MTT, every hole adds 100 μ l DMSO and vibrated 10 minutes, abundant dissolving crystallized thing, the 490nm place measures the absorbance A value, and experimental result is represented (experimental group A value/control group A value * 100) with cell proliferation rate.The result shows (seeing Table 2), compares with the blank group, and gingkolic acid tincture of the present invention can suppress the propagation of apocrine gland cell, and the apocrine gland cell is had tangible destruction.
The influence of table 2. pair apocrine gland cell proliferation
X ± s.n=12. compares with blank, * * P＜0.01.
The local irritation experiment: get 8 of adult rabbit, male and female half and half, every animal sub-cage rearing was raised 3-4 days at laboratory condition earlier.Then rabbit spinal column both sides dorsal body setae is shaved off every lateral area 5 * 10cm with electric shaver-for women
2Whether scrutiny depilation district has redness and damage, if any abandoning it, can not test.Adopt the test method of multiple dosing, gingkolic acid external preparation of the present invention is smeared in the district in depilation, every day 2 times, smears continuously 7 days.Whether last is smeared after 24 hours with warm water flush away smear, observes the local skin reaction after 1,24,48,72 hour, as erythema, edema, desquamation, incrustation etc., have petechia, skin peptide coarse or poor etc., record time of origin and regression time.Experimental result shows, is smearing gingkolic acid external preparation of the present invention continuously after 7 days, and each rabbit skin does not all show tangible skin irritation and anaphylaxis.Show product safety of the present invention, have no adverse reaction.
The clinic trial test: on probation through the fetid sweat patient in order to the gingkolic acid external preparation that the top method is made, concrete case sees Table 3.All patients are coated with skin abnormal flavour place outward with the present invention, every day 1 time, continuous 5 days.The patient does not all use any other external preparation for skin medicine during treating.Efficacy assessment standard: recovery from illness: local lossless or hypohidrosis, no stink is followed up a case by regular visits to and was not had recurrence in 1 year; Effectively: local perspiration obviously reduces, and no stink or stink obviously alleviate, and recurrence (but before obviously being lighter than medication) is arranged after the drug withdrawal, needs intermittent use; Invalid: ephidrosis does not have minimizing, and stink does not have and alleviates.Cure rate=healing number/total case X100%; Effective percentage=(healing number+effective number)/total case X100%.The results are shown in Table 3.Clinic trial result shows that multiple fetid sweat patient uses gingkolic acid external preparation of the present invention all effective, and effective percentage reaches 100%; Cure rate is all above 95%.All patients untoward reaction such as skin irritation, allergy all do not occur during using the present invention.Therefore the present invention is a kind of external preparation of desirable treatment fetid sweat, and is evident in efficacy, safe and reliable.
The clinical effectiveness of table 3 gingkolic acid external preparation treatment of the present invention fetid sweat
Get bromhidrosis patient axillary secretions and do the antibacterial culture experiment: 30 routine patients get dorsal position, and two upper limb abductions, elbow in the wrong are after both hands place pillow.Dip in the cotton swab of the moistening mistake of normal saline and to get axillary secretions, send laboratory to do the antibacterial culture experiment in 10 minutes, 28 routine patients turn out the staphylococcus epidermidis growth, and 2 examples are turned out staphylococcus aureus growth.Preparation Carnis Bovis seu Bubali cream fluid medium: Carnis Bovis seu Bubali cream 0.3g, peptone 1.0g, sodium chloride 0.5g adds distilled water again to 100ml after adding a small amount of distilled water heat fused, and adjust pH to 7.2 filters, sterilization.Cotton swab dips in gets patient's axillary secretions, is inoculated in the test tube that contains Carnis Bovis seu Bubali cream soup body culture medium, and every pipe 1ml cultivated 24 hours in 37 ℃ of incubators, observed the bacterial growth situation.As liquid clarification in vitro, represent no bacterial growth; As be muddy, the expression antibacterial grows.Result of the test shows that the muddiness of liquid in vitro of axillary secretions inoculation illustrates that there is bacterial infection the patient oxter before the patient treatment; After the gingkolic acid external preparation of the present invention treatment, the clarification of liquid in vitro of patient's axillary secretions inoculation illustrates that gingkolic acid external preparation of the present invention can remove the oxter bacterial infection, has antibacterial action.
Get bromhidrosis patient axillary secretions and measure ammonia-nitrogen content, can reflect the amount of protein catabolite in the axillary secretions; What of organic acidic material mensuration axillary secretions pH value can react; And free content of fatty acid in the mensuration axillary secretions.With aseptic medicated napkin wiping bromhidrosis patient armpit, insert 25ml and do not have in the ammonia, measure solution acidity value, ammonia-nitrogen content and free fatty acid content.Measure the solution acidity value with pH meter.The nessler reagent photometry is one of standard method of measuring at present ammonia nitrogen.Get the 25ml color comparison tube, add the ammonia nitrogen standard and use liquid 0.00,0.25,0.5,1.0,2.0,3.0 4.0,5.0ml adds no ammonia and is diluted to scale, add the 0.5ml potassium sodium tartrate solution, 0.5ml nessler reagent, mixing, 10min develops the color in 25 ℃ of water-baths, with the 1cm cuvette at 420nm place colorimetric determination absorbance, with ammonia-nitrogen content to absorbance production standard curve.Nessler reagent: prepare with KI and HgI2, KOH according to the GB/T5750.5-2006 method.Sodium potassium tartrate tetrahydrate: take by weighing the 50g sodium potassium tartrate tetrahydrate and be dissolved in 100ml and do not have in the ammonia, add the NaOH5ml of 250g/L, heated and boiled is settled to 100ml to about 50ml after the cooling.Measure free fatty acid content with detection kit.Experimental result sees Table 4.The result shows that the present invention can reduce bromhidrosis patient armpit cleaning piece solution pH value, illustrates that the present invention can reduce the generation of oxter organic acid substance.The present invention can reduce the ammonia nitrogen compounds content of bromhidrosis patient armpit cleaning piece solution, illustrates that the present invention can obviously suppress the decomposition of oxter perspiration protein, reduces the generation of ammonia nitriding compound stink substance.Experimental result shows that also the present invention can reduce the free fatty acid content of bromhidrosis patient armpit cleaning piece solution, illustrates that the present invention can suppress steatolysis, reduces the catabolite free fatty acid content, thereby reduces the generation of odor causing substance.
Table 4 gingkolic acid external preparation of the present invention is to the influence of axillary secretions
X ± s.n=30. compares with model group, * P＜0.05, * * P＜0.01.
The present invention is compared with prior art: the present invention derives from natural precious medicinal plants Semen Ginkgo, from Folium Ginkgo, really, position extraction separation gingkolic acid such as episperm, be that effective ingredient is made preparation for external application to skin with the gingkolic acid, have disinfection, convergence hidroschesis, infiltrate skin and destroy apocrine gland, suppress the good action that odor causing substance produces; Fetid sweat is had significant radical cure effect, and curative effect is outstanding, use safety has no side effect, and has good potential applicability in clinical practice.
Claims (6)
1. gingkolic acid is prevented and treated purposes in the external preparation of fetid sweat, hyperhidrosis, chromhidrosis in preparation, and wherein gingkolic acid is the unique active component in the external preparation, contains the gingkolic acid of 0.5-20% by weight percentage in described external preparation.
2. the purposes of gingkolic acid as claimed in claim 1, described fetid sweat is armpit, foot or perineal position fetid sweat.
3. the purposes of gingkolic acid as claimed in claim 1, described external preparation is medicine, cosmetics or disinfectant external preparation.
4. the purposes of gingkolic acid as claimed in claim 1, described external preparation is liquid preparation, cream cream, gel, powder, membrane or aerosol spray.
5. the purposes of gingkolic acid as claimed in claim 1, described external preparation is lotion or transdermal absorption formulation.
6. as each described purposes among the claim 1-3, it is characterized in that described gingkolic acid is by the Chemical Decomposition method, from the leaf of Semen Ginkgo, really, obtain the extract of episperm, rhizome; Or to Folium Ginkgo, really, episperm, rhizome extract elaboration products and reclaim again in the remaining waste material in extracting the course of processing and obtain; Or the method by chemosynthesis obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110236658 CN102349919B (en) | 2011-08-18 | 2011-08-18 | Application of gingkolic acid in preparation of external preparation for treating osmidrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110236658 CN102349919B (en) | 2011-08-18 | 2011-08-18 | Application of gingkolic acid in preparation of external preparation for treating osmidrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102349919A CN102349919A (en) | 2012-02-15 |
| CN102349919B true CN102349919B (en) | 2013-08-14 |
Family
ID=45573635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110236658 Expired - Fee Related CN102349919B (en) | 2011-08-18 | 2011-08-18 | Application of gingkolic acid in preparation of external preparation for treating osmidrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102349919B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3068366B1 (en) * | 2013-11-13 | 2020-07-15 | L'oreal | Use as a deodorant agent of a salified salicylic acid derivative, alone or in a mixture |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6086883A (en) * | 1993-12-03 | 2000-07-11 | Montana Limited | Extract from the leaves of Ginkgo biloba |
| CN1747715A (en) * | 2003-04-07 | 2006-03-15 | 花王株式会社 | Deodorant agent |
| CN1763209A (en) * | 2005-09-26 | 2006-04-26 | 江南大学 | Comprehensive utilization process for gingko episperm |
-
2011
- 2011-08-18 CN CN 201110236658 patent/CN102349919B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6086883A (en) * | 1993-12-03 | 2000-07-11 | Montana Limited | Extract from the leaves of Ginkgo biloba |
| CN1747715A (en) * | 2003-04-07 | 2006-03-15 | 花王株式会社 | Deodorant agent |
| CN1763209A (en) * | 2005-09-26 | 2006-04-26 | 江南大学 | Comprehensive utilization process for gingko episperm |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3068366B1 (en) * | 2013-11-13 | 2020-07-15 | L'oreal | Use as a deodorant agent of a salified salicylic acid derivative, alone or in a mixture |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102349919A (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101183075B1 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
| CN103893345B (en) | Composition containing a natural extract | |
| CN110731991A (en) | Skin external composition with acne removing effect | |
| CN110731921A (en) | Skin external composition with acne removing effect | |
| CN108143639A (en) | A kind of acne eliminating cream and preparation method thereof | |
| CN104688786A (en) | Externally used pharmaceutical composition, preparation method and application thereof | |
| CN102038733B (en) | Externally-used traditional Chinese medicine for treating hypertrophic scar and preparation method thereof | |
| CN109260059A (en) | A kind of essential oil composition with anti-acne and skin repair and application | |
| CN102641278A (en) | Application of ginkgolic acid in treating arthritis | |
| CN101791285B (en) | Clausenamide composite nanometer emulsion for clearing facial age pigment (lipofuscin) and preparation method thereof | |
| CN105963243B (en) | A kind of borneol cinnamomum camphora essential oil sustained release emulsifiable paste and preparation method thereof for treating acne vulgaris | |
| CN103432049B (en) | Composition with deodorization function | |
| CN102349919B (en) | Application of gingkolic acid in preparation of external preparation for treating osmidrosis | |
| CN115212243A (en) | Application of epimedium extract | |
| CN101904808A (en) | Composition for reducing irritation and inflammation in skin | |
| US20040109899A1 (en) | Antiviral medicament and method for producing and using the same for the prophylactic and therapeutic treatment of papillomavirus induced tumors, lesions and deseases | |
| KR100887294B1 (en) | Cosmetic compositions containing hollyhock extracts | |
| CN102319272B (en) | Application of ginkgolic acid in preparation of external preparation for treating dermatopathy | |
| CN102846677A (en) | Use of ginkgolic acids in preparation of external preparation for treating cutaneous tumors | |
| CN112516183B (en) | Preparation method and application of extract with repair effect on trauma | |
| CN103751229A (en) | Application of gingko extract nanometer liposome in bromidrosis treatment | |
| CN102283869A (en) | Application of ginkgo extract in preparation of external preparation for treating osmidrosis | |
| Kisacik et al. | Effectiveness of bitter melon extract in the treatment of ischemic wounds in rats | |
| CN102846678A (en) | Application of ginkgolic acid in weight losing | |
| KR20160122052A (en) | Composition for treating wound containing stellera chamaejasme extract or fraction thereof and method for treating wound in a subject |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lei Hong Inventor after: Wang Qing Inventor before: Wang Qing Inventor before: Lei Hong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG QING LEI HONG TO: LEI HONG WANG QING |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130814 |